BD (NYSE:BD) picked up a legal victory in a patent spat with Baxter (NYSE:BAX) over a system for moving drugs.
A federal judge in Chicago ruled that BD’s PhaSeal system for transporting hazardous drugs between syringes and vials doesn’t infringe two patents belonging to Baxter.
U.S. District Judge Joan H. Lefkow granted BD summary judgment on two patent claims and resolved all claims in its favor. She denied BD’s motion for summary judgment on willfulness and damages as moot. She also denied Baxter’s motion for partial summary judgment as moot, terminating the case.
Baxter had alleged that the combination of two components of the PhaSeal system — the “protector” and “injector” — form a device that infringes on three of its patents, each entitled “Sliding Reconstitution Device With Seal.”
Get the full story at our sister site, Drug Delivery Business News.
